Custom cancer vaccine fights deadly eye tumor recurrence

NCT ID NCT01983748

First seen Feb 01, 2026 · Last updated Apr 21, 2026 · Updated 11 times

Summary

This study tested whether a personalized vaccine could prevent cancer from returning in patients with a high-risk form of eye melanoma. After having their tumor surgically removed, 200 patients either received a vaccine made from their own tumor cells and immune cells over two years, or were simply monitored. The goal was to see if the vaccine could help the body's immune system recognize and destroy any remaining cancer cells to keep patients cancer-free longer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dept. of Dermatology, University Hospital

    Erlangen, Bavaria, 90154, Germany

  • Städtisches Klinikum

    Dessau, 06847, Germany

  • University Hospital Department of Ophtalmology

    Erlangen, Bavaria, 91054, Germany

  • University Hospital Department of Ophtalmology

    Würzburg, Bavaria, 97080, Germany

  • University Hospital Department of Ophtalmology

    Essen, 45122, Germany

  • University Hospital Department of Ophtalmology

    Homburg/Saar, 66421, Germany

  • University Hospital Department of Ophtalmology

    Lübeck, 23538, Germany

  • University Hospital Department of Ophtalmology

    Tübingen, 72076, Germany

Conditions

Explore the condition pages connected to this study.